Literature DB >> 28050271

Evolution of Tumor Clones in Adult Acute Lymphoblastic Leukemia.

S Yu Smirnova1, Yu V Sidorova1, N V Ryzhikova1, K A Sychevskaya2, E N Parovichnikova1, A B Sudarikov1.   

Abstract

Clonal instability of a tumor cell population in acute lymphoblastic leukemia (ALL) may complicate the monitoring of a minimal residual disease (MRD) by means of patient-specific targets identified at the disease onset. Most of the data concerning the possible instability of rearranged clonal TCR and IG genes during disease recurrence were obtained for ALL in children. The appropriate features of adult ALL, which are known to differ from those of childhood ALL in certain biological characteristics and prognosis, remain insufficiently studied. The aim of this study was to assess the stability of IG and TCR gene rearrangements in adult ALL. Rearrangements were identified according to the BIOMED-2 protocol (PCR followed by fragment analysis). Mismatch in clonal rearrangements at onset and relapse was identified in 83% of patients, indicating clonal instability during treatment. Clonal evolution and diversity of IG and TCR gene rearrangements may be one of the tumor progression mechanisms. New rearrangements may emerge due to residual VDJ-recombinase activity in tumor cells. Also, many clonal IG and TCR gene rearrangements may be present at different levels at a diagnosis, but less abundant clones may be "invisible" due to limited detection sensitivity. Later, major clones may disappear in the course of chemotherapy, while others may proliferate. Investigation of clonal evolution and heterogeneity in ALL and their impact on the treatment efficacy will contribute to the identification of new prognostic factors and the development of therapeutic approaches.

Entities:  

Keywords:  IG and TCR gene rearrangements; acute lymphoblastic leukemia; relapse

Year:  2016        PMID: 28050271      PMCID: PMC5199211     

Source DB:  PubMed          Journal:  Acta Naturae        ISSN: 2075-8251            Impact factor:   1.845


  29 in total

Review 1.  Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.

Authors:  V H J van der Velden; A Hochhaus; G Cazzaniga; T Szczepanski; J Gabert; J J M van Dongen
Journal:  Leukemia       Date:  2003-06       Impact factor: 11.528

2.  Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia.

Authors:  T Flohr; A Schrauder; G Cazzaniga; R Panzer-Grümayer; V van der Velden; S Fischer; M Stanulla; G Basso; F K Niggli; B W Schäfer; R Sutton; R Koehler; M Zimmermann; M G Valsecchi; H Gadner; G Masera; M Schrappe; J J M van Dongen; A Biondi; C R Bartram
Journal:  Leukemia       Date:  2008-01-31       Impact factor: 11.528

3.  Quantification of minimal residual disease in children with oligoclonal B-precursor acute lymphoblastic leukemia indicates that the clones that grow out during relapse already have the slowest rate of reduction during induction therapy.

Authors:  V de Haas; O J Verhagen; A E von dem Borne; W Kroes; H van den Berg; C E van der Schoot
Journal:  Leukemia       Date:  2001-01       Impact factor: 11.528

4.  Relapse in children with acute lymphoblastic leukemia involving selection of a preexisting drug-resistant subclone.

Authors:  Seoyeon Choi; Michelle J Henderson; Edward Kwan; Alex H Beesley; Rosemary Sutton; Anita Y Bahar; Jodie Giles; Nicola C Venn; Luciano Dalla Pozza; David L Baker; Glenn M Marshall; Ursula R Kees; Michelle Haber; Murray D Norris
Journal:  Blood       Date:  2007-03-19       Impact factor: 22.113

Review 5.  The biology and treatment of acute lymphoblastic leukemia in adults.

Authors:  E A Copelan; E A McGuire
Journal:  Blood       Date:  1995-03-01       Impact factor: 22.113

Review 6.  Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance.

Authors:  D Campana; C H Pui
Journal:  Blood       Date:  1995-03-15       Impact factor: 22.113

7.  Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia.

Authors:  M J Pongers-Willemse; T Seriu; F Stolz; E d'Aniello; P Gameiro; P Pisa; M Gonzalez; C R Bartram; E R Panzer-Grümayer; A Biondi; J F San Miguel; J J van Dongen
Journal:  Leukemia       Date:  1999-01       Impact factor: 11.528

8.  Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor-B-ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease.

Authors:  Tomasz Szczepański; Marja J Willemse; Bas Brinkhof; Elisabeth R van Wering; Mirjam van der Burg; Jacques J M van Dongen
Journal:  Blood       Date:  2002-04-01       Impact factor: 22.113

9.  CREBBP mutations in relapsed acute lymphoblastic leukaemia.

Authors:  Charles G Mullighan; Jinghui Zhang; Lawryn H Kasper; Stephanie Lerach; Debbie Payne-Turner; Letha A Phillips; Sue L Heatley; Linda Holmfeldt; J Racquel Collins-Underwood; Jing Ma; Kenneth H Buetow; Ching-Hon Pui; Sharyn D Baker; Paul K Brindle; James R Downing
Journal:  Nature       Date:  2011-03-10       Impact factor: 49.962

10.  Southern blot patterns, frequencies, and junctional diversity of T-cell receptor-delta gene rearrangements in acute lymphoblastic leukemia.

Authors:  T M Breit; I L Wolvers-Tettero; A Beishuizen; M A Verhoeven; E R van Wering; J J van Dongen
Journal:  Blood       Date:  1993-11-15       Impact factor: 22.113

View more
  2 in total

1.  Isolation and characterization of spontaneously immortalized B-lymphocyte lines from HIV-infected patients with and without non-Hodgkin's Lymphoma.

Authors:  Ke Zhuang; Yongxi Zhang; Li Zhou; Xiaoying Qi; Xiqiu Xu; Fengzhen Meng; Zhigao Xu; Jinbiao Liu; Liang Shao; Huan Liu; Hang Liu; Jun Fang; Di Deng; Jianhong Peng; Fuling Zhou; Li Liu; Hongbin Tang; Yong Xiong; Wenzhe Ho; Deying Guo; Hengning Ke; Xien Gui
Journal:  Cancer Med       Date:  2019-09-20       Impact factor: 4.452

Review 2.  Next-generation sequencing for MRD monitoring in B-lineage malignancies: from bench to bedside.

Authors:  Xinyue Deng; Meilan Zhang; Jianfeng Zhou; Min Xiao
Journal:  Exp Hematol Oncol       Date:  2022-09-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.